Significance of multi-drug-resistant proteins in predicting chemotherapy response and prognosis in epithelial ovarian cancer

Journal of Obstetrics and Gynaecology Research

Volumn 25, Issue 6, 1999, Pages 387-394

  Yokoyama, Yoshihito ^a   Sato, Shigemi ^a   Fukushi, Yoshiyuki ^a   Sakamoto, Tomomi ^a   Futagami, Masayuki ^a   Saito, Yoshiharu ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

Chemotherapy resistance; Epithelial ovarian cancer; MDR related proteins; Prognosis

Indexed keywords

ANTIBODY; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; PROTEIN C JUN;

ARTICLE; CANCER SURVIVAL; CHEMOTHERAPY; DRUG RESISTANCE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CANCER; PROGNOSIS; PROTEIN EXPRESSION;

EID: 0033386787     PISSN: 13418076     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1447-0756.1999.tb01182.x     Document Type: Article

References (33)

1. Hamada S, Kamada M, Furumoto H, Hirao T, Aono T. Expression of glutathione S-transferase π in human ovarian cancer as an indicator of resistance to chemotherapy. Gynecol Oncol 1994; 52: 313-319
2. Johnson SW, Ozols RF, Hamilton TC. Mechanisms of drug resistance in ovarian cancer. Cancer 1993; 71 (Suppl): S644-S649
3. Mannervik B, Danielson UH. Glutathione transferases - structure and catalytic activity. CRC Crit Rev Biochem Mol Biol 1988; 23: 283-337
4. Ishikawa T, Ali-Osman F. Glutathione-associated cis-diamminedichloroplatinum (II) metabolism and ATP-dependent efflux from leukemia cells. J Biol Chem 1993; 268: 20116-20125
5. Goto S, Yoshida K, Morikawa T, Urata Y, Suzuki K, Kondo T. Augmentation of transport for cisplatin-glutathione adduct in cisplatin-resistant cancer cells. Cancer Res 1995; 55: 4297-4301
6. Kodate C, Fukushi A, Narita T, Kudo H, Soma Y, Sato K. Human placental form of glutathione S-transferase (GST-π) as a new immunohistochemical marker for human colonic carcinoma. Jpn J Cancer Res (Gann) 1986; 77: 226-229
7. Batist G, Tulpule A, Sinha BK, Katki AG, Meyers CE, Cowan KH. Overexpression a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem 1986; 261: 15544-155449
8. Waxman DJ. Glutathione S-transferases: Role in alkylating agent resistance and possible target for modulaion chemotherapy - a review. Cancer Res 1990; 50: 6449-6454
9. Tsuchida S, Sato K. Glutathione transferases and cancer. Crit Rev Biochem Mol Biol 1992; 27: 337-384
10. Morrow CS, Goldsmith ME, Cowan KH. Regulation of human glutathione S-transferase π gene transcription: Influence of 5′-flanking sequences and trans-activating factors which recognize AP-1 binding site. Gene 1990; 88: 215-225
11. Xia CL, Cowell IG, Dixon KH, Pemble SE, Ketterer B, Taylor JB. Glutathione transferase π. Its minimal promoter and downstream cis-acting element. Biochem Biophys Res Commun 1991; 176: 233-240
12. Moffat GJ, McLaren AW, Wolf CR. Involvement of Jun and Fos proteins in regulating transcriptional activation of the human pi class glutathione S-transferase gene in multidrug-resistant MCF7 breast cancer cells. J Biol Chem 1994; 269: 16397-16402
13. Angel P, Allegretto EA, Okino ST, Hattori K, Boyle WT, Hunter T. Oncogene jun encodes a sequence-specifictrans-activator similar to AP-1. Nature 1988; 332: 166-171
14. Yokoyama Y, Sato S, Tsuchida S, Saito Y. Prognostic significance of glutathione S-transferase π and c-Jun in epithelial ovarian cancers. Int J Clin Oncol 1998; 3: 281-286
15. Biedler JL. Genetic aspects of multidrug resistance (review). Cancer 1992; 70: 1799-1809
16. Broxterman HJ, Giaccone G, Lankelma J. Multidrug resistance proteins and other drug trans-port-related resistance to natural product agents. Curr Opin Oncol 1995; 7: 532-540
17. Nooter K, Westerman AM, Flens MJ, et al. Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin Cancer Res 1995; 1: 1301-1310
18. Zaman GJR, Flens MJ, van Leusden MR, et al The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci. USA 1994; 91: 8822-8826
19. Muller M, Meijer C, Zaman GJR, Borst P, Scheper RJ, Mulder NH, De Vries EGE, Jansen PLM. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci USA 1994; 91:13033-13037
20. Sikic BI. Modulation of multidrug resistance. J Clin Oncol 1993; 11: 1629-1635
21. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214
22. Flens MJ, Zaman GJR, van der Valk P, et al. Tissue distribution of the multidrug resistance-associated protein (MRP). Am J Pathol 1996; 148: 1237-1247
23. Hirazono K, Shinozuka T, Kuroshima Y, Itoh H, Kawai K. Immunohistochemical expression of glutathione S-transferase π (GST-π) and chemotherapy response in malignant tumors. J Obstet Gynaecol 1995; 21: 305-312
24. Izquierdo MA, van der Zee AGJ, Vermorken JB, et al. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognosis in advanced ovarian carcinoma. J Natl Cancer Inst 1995; 87:1230-1237
25. Schroeijers AB, Scheffer GL, Flens MJ, Meijer GA, Izquierdo MA, van der Valk P, Scheper RJ. Immunohistochemical detection of the human major vault protein LRP with two monoclonal antibodies in formalin-fixed, paraffin-embedded tissues. Am J Pathol 1998; 152: 373-378
26. Sharp SY, Smith V, Hobbs S, Kelland LR. Lack of a role for MRP1 in platinum drug resistance in human ovarian cancer cell lines. Br J Cancer 1998; 78: 175-180
27. Holzmayer TA, Hilsenbeck S, von Hoff DD, Reninson IB. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst 1992; 84: 1486-1491
28. van der Zee AGJ, Hollema H, Suurmeijer AJH, Krans M, Sluiter WJ, Willemse PHB, Aalders JG, de Vries EGE. Value of P-glycoprotein, glutathione S-transferase pi, c-erb B-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 1995; 13: 70-78
29. Volm M, van Kaick G, Mattern J. Analysis of c-fos, c-jun, c-erbB1, c-erbB2, and c-myc in primary lung carcinomas and their lymph node metastases. Clin Exp Metastasis 1994; 12: 329-334
30. Tiniakos DG, Mellon K, Anderson JJ, Robinson MC, Neal DE, Home CHW. c-jun oncogene expression in transitional cell carcinoma of the urinary bladder. Br J Urol 1994; 74: 757-761
31. Neal ED, Mellon K. Epidermal growth factor receptor and bladder cancer: A review. Urol Int 1992; 48: 365-371
32. Kigawa J, Minagawa Y, Itamochi H, Kanamori Y, Ishihara H, Terakawa N. Retroperitoneal lymphadenectomy, including the para-aortic nodes in patients with stage III ovarian cancer. Am J Clin Oncol 1994; 17: 230-233
33. Cole Sp, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM, Deeley RG. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 1994; 54: 5902-5910